Issues
-
Cover Image
Cover Image
In vivo effects of p53p-Ant administered by convection-enhanced delivery. Male Fisher rats had control peptide (p53p and Ant) or p53p-Ant infused over a 6-h period by a convection-enhanced delivery system and repeated once, separated by a hiatus of 12 h. Animals were monitored for adverse symptoms such as ataxia or seizure and sacrificed 12 h after the second infusion of peptide (total 36 h). Brains were immediately fixed, sectioned, and stained for presence of apoptosis using the TUNEL method. Top, morphological pictures; bottom, percentage of apoptotic cells. For details, see article by Senatus et al. in this issue.
- PDF Icon PDF LinkTable of Contents
ARTICLE
Restoration of p53 function for selective Fas-mediated apoptosis in human and rat glioma cells in vitro and in vivo by a p53 COOH-terminal peptide
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels
Differential competitive resistance to methylating versus chloroethylating agents among five O6-alkylguanine DNA alkyltransferases in human hematopoietic cells
Novel angiogenic inhibitor DN-9693 that inhibits post-transcriptional induction of connective tissue growth factor (CTGF/CCN2) by vascular endothelial growth factor in human endothelial cells
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds